

# Q3 2022 BUSINESS UPDATE

NOVEMBER 8, 2022



# DISCLAIMER

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.





long lived plasma cell

Q3 2022. BUSINESS UPDATE SUMMARY.

# 10 YEARS AT THE CUTTING EDGE OF ANTIBODY DISCOVERY

**\$868M**

in cash, cash equivalents  
& marketable securities

**164**

cumulative programs  
under contract

**92**

cumulative  
programs started

**7**

molecules in  
the clinic



# CREATE VALUE BY POWERING INNOVATION. CAPTURE VALUE THROUGH SHARED SUCCESS.

## PARTNER-INITIATED PROGRAMS

### Discovery Programs



### Co-Development Programs



## TECHNOLOGY-DEVELOPMENT

### Pre-Partnered Programs





# 2 DISCOVERY PROGRAMS ADVANCE INTO PRECLINICAL AND CLINICAL DEVELOPMENT

## ***REGENERON***

---

### **FIRST**

candidate to advance into further preclinical development

**GPCR target**

**4** targets  
multi-year

 multiple indications

## **undisclosed**

---

**1** MOLECULE  
ENTERED THE CLINIC

 Alzheimer's Disease





PRE-PARTNERED PROGRAMS. CREATING VALUE THROUGH TECHNOLOGY-DEVELOPMENT.

# UNRIVALED ABILITY TO **BREAK THE BARRIERS** OF CONVENTIONAL DRUG DISCOVERY.



## T-Cell Engager Platform

**Hundreds of diverse** CD3-binding antibodies to combine to create optimized precision cancer therapies.

**Clinically-validated** OrthoMab™ bispecifics platform, to pair CD3-targeting and **tumor-targeting antibodies**.

Internal validation of panel through work on **three well-recognized and high-value targets**.



## GPCRs & Ion Channels Platform

**Clinically validated**, membrane-protein targets with **large commercial potential** that have proven largely intractable using traditional methods for antibody discovery.

Internal platform integrated across the best of modern **data science and biotechnology to generate best-in-class candidates**.



# Q3 2022

## FINANCIALS UPDATE



# Strong portfolio growth.


Total # of

**Programs Under Contract** **164**

Total # of


**Discovery Partners** **38**

Cumulative # of  
**Program Starts**



- WITHOUT downstream participation  
 + WITH downstream participation

Cumulative # of  
**Molecules in the Clinic**








Note: Showing year-end figures except for most recent quarter.  
Historical results are not necessarily indicative of future results.






Now 7 molecules in the clinic.

| MOLECULE                            | STAGE                                       | PARTNER   | THERAPEUTIC AREA  | PROGRAM TYPE                    |
|-------------------------------------|---|---|---|---------------------------------|
| <b>bamlanivimab</b><br>(LY-CoV555)  | Marketed, Emergency Use Authorization (EUA) |    | <ul style="list-style-type: none"> <li>infectious disease – COVID-19</li> </ul>                                     | AbCellera Discovery Partnership |
| <b>bebtelovimab</b><br>(LY-CoV1404) | Marketed, Emergency Use Authorization (EUA) |    | <ul style="list-style-type: none"> <li>infectious disease – COVID-19</li> </ul>                                     |                                 |
| <b>NEW undisclosed</b>              | Phase 1                                     | undisclosed   | <ul style="list-style-type: none"> <li>neurology – Alzheimer’s Disease</li> </ul>                                   |                                 |
| <b>NBL-012</b>                      | Phase 1                                     |    | <ul style="list-style-type: none"> <li>dermatology</li> <li>gastrointestinal disease</li> <li>immunology</li> </ul> | Trianni License                 |
| <b>NBL-015</b>                      | IND/CTA authorized                          |   | <ul style="list-style-type: none"> <li>oncology</li> </ul>  |                                 |
| <b>undisclosed</b>                  | IND/CTA authorized                          | undisclosed   | <ul style="list-style-type: none"> <li>undisclosed</li> </ul>   |                                 |
| <b>IVX-01</b>                       | Clinical field study                        |  | <ul style="list-style-type: none"> <li>animal health</li> </ul>   | AbCellera Discovery Partnership |

As of September 30, 2022



\$101.4M total revenue, driven by royalties for bebtelovimab.







# Operating expenses reflect ongoing investments.

Operating Expenses USD


## RESEARCH & DEVELOPMENT



## SALES & MARKETING



## GENERAL & ADMIN









Net earnings of \$26.6M: equivalent to \$0.09<sub>(basic)</sub> and \$0.08<sub>(diluted)</sub> per share.

Earnings USD


### NET EARNINGS



### EARNINGS PER SHARE: BASIC




### EARNINGS PER SHARE: DILUTED





Nearly 900 million in total cash, equivalents, and marketable securities.

Cash Flows USD



\* Restricted cash (including restricted cash in other assets)



# THANK YOU

